Special Issues
Table of Content

Integrative Strategies in Cancer Therapy

Submission Deadline: 31 July 2026 View: 333 Submit to Special Issue

Guest Editor(s)

Dr. Stefano Mancin

Email: stefano.mancin@humanitas.it

Affiliation: Cancer Center, Clinical Nutrition Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy

Homepage:

Research Interests: Nutrition, Cancer, Supportive Care

图片1.png


Dr. Giovanni Cangelosi

Email: giovanni01.cangelosi@unicam.it

Affiliation: School of Pharmacy, Polo Medicina Sperimentale e Sanità Pubblica, 62032 Camerino, Italy

Homepage:

Research Interests: Chronic disease, cancer

图片2.png


Dr. Alessio Lo Cascio

Email: locascio.alessio@lamaddalenanet.it

Affiliation: La Maddalena Cancer Center, Palermo, 90146, Italy

Homepage:

Research Interests: Supportive Care, Nursing

图片3.png


Dr. Marco sguanci

Email: sguancim@gmail.com

Affiliation: Società Infermieri di Area Nefrologica (SIAN) Via Capotesta 1/30, 07026 Olbia, Italy

Homepage:

Research Interests: Cancer, Nutrition


Dr. Sara Morales Palomares

Email: sara.morales@unical.it

Affiliation: Department of Pharmacy, Health and Nutritional Sciences (DFSSN), University of Calabria, Rende, 87036, Italy

Homepage:

Research Interests: Chronic disease, Supportive Care

图片4.png


Summary

Advances in cancer therapy increasingly highlight the importance of a comprehensive and patient-centered approach that extends beyond tumor eradication. Modern oncology integrates molecular research, immunotherapy, and precision medicine with supportive interventions aimed at improving treatment tolerance, therapeutic response, and long-term outcomes. Among these, metabolic modulation and supportive care strategies—including nutrition, exercise, and symptom management—are gaining recognition for their role in optimizing therapy efficacy and enhancing patients' quality of life.


This Special Issue invites contributions exploring how innovative therapeutic approaches, from molecular and metabolic targets to multimodal clinical interventions, can be integrated within modern cancer care. Topics of interest include the interplay between tumor metabolism and treatment response, the role of supportive therapies in mitigating toxicity, and emerging technologies—such as digital health tools and artificial intelligence—for personalized oncology.
By fostering a multidisciplinary dialogue between basic scientists and clinicians, this collection aims to redefine the concept of "integrated cancer therapy," bridging bench and bedside to improve outcomes and quality of life for cancer patients.


Keywords

Cancer therapy; tumor metabolism; supportive care; immunotherapy; metabolic modulation; personalized oncology; digital health; translational research; clinical innovation.

Published Papers


  • Open Access

    REVIEW

    Induction Therapy Followed by Surgery in Advanced Thymic Epithelial Tumors: A 20-Year Systematic Review and Meta-Analysis

    Giovanni Leuzzi, Michele Ferrari, Federica Sabia, Alessandro Pardolesi, Alessia Stanzi, Claudia Proto, Giuseppe Lo Russo, Arsela Prelaj, Monica Ganzinelli, Matteo Calderoni, Clarissa Uslenghi, Ugo Pastorino, Piergiorgio Solli
    Oncology Research, DOI:10.32604/or.2026.077158
    (This article belongs to the Special Issue: Integrative Strategies in Cancer Therapy)
    Abstract Backgrounds: Despite the availability of multimodal strategies, no universally accepted guidelines exist for the management of advanced Thymic Epithelial Tumors (TETs), particularly in locally advanced thymomas. The aim of this study was to evaluate the oncological and surgical outcomes of induction therapy (IT) followed by surgery in patients with Masaoka–Koga stage III–IVA TETs. To this end, we conducted a systematic review and meta-analysis assessing surgical-pathological and survival outcomes. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was performed.… More >

    Graphic Abstract

    Induction Therapy Followed by Surgery in Advanced Thymic Epithelial Tumors: A 20-Year Systematic Review and Meta-Analysis

  • Open Access

    ARTICLE

    Extracellular Signal-Regulated Kinase and Reactive Oxygen Species Regulate PD-L1 to Promote Migration and Proliferation of Triple-Negative Breast Cancer MDA-MB-231 Cells

    Ching-Chun Ho, Yen-Cheng Chen, Wei-Liang Lean, Wen-Sheng Wu
    Oncology Research, DOI:10.32604/or.2026.077693
    (This article belongs to the Special Issue: Integrative Strategies in Cancer Therapy)
    Abstract Objectives: Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer. Mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK), as well as protein kinase B (AKT), are potential therapeutic targets for TNBC. Programmed death-ligand 1 (PD-L1) is implicated in TNBC progression and is associated with AKT and ERK signaling pathways. In addition, reactive oxygen species (ROS) act upstream of MAPK/AKT and PD-L1. In this study, we aimed to clarify the role of PD-L1 in TNBC progression and to delineate the underlying signaling mechanisms. Methods: Western blotting and reverse… More >

Share Link